Generex Initiates Enrollment for Phase I Cancer Combination Therapy Trial
Posted on: Friday, 8 August 2008, 12:00 CDT
Generex Biotechnology has initiated enrollment of patients for a new Phase I clinical trial employing a immunotherapeutic cancer vaccine being developed at Antigen Express, its wholly-owned subsidiary.
The new trial will employ two immunotherapeutic vaccines designed to work in concert to activate the immune system to recognize and kill tumor cells in breast and ovarian cancer patients.
The new trial will use the Antigen Express AE37 vaccine combined with another peptide vaccine to establish both safety and immunological response. Currently the AE37 vaccine is the subject of a Phase II clinical trial in patients with breast cancer and a Phase I trial in prostate cancer patients. Both vaccines are derived from the tumor-related HER-2/neu protein.
The trial is being conducted as part of collaboration between Antigen Express, George Peoples at the Brooke Army Medical Center and the Mary Crowley Cancer Center, which is funding the trial.
Source: Datamonitor
Related Articles
- Generex Biotechnology Phase I Trial Results for Novel Immunotherapy Vaccine in Breast Cancer Patients Presented At ASCO
- First Prostate Cancer Patients Treated in a Phase I Clinical Trial As Part of a Collaboration Between Generex Biotechnology and the Saint Savas Cancer Hospital
- Array BioPharma Advances ErbB-2 Inhibitor, ARRY-380, into Phase 1 Cancer Patient Trial
- Affymax Presents Results From Ongoing Phase 2 Clinical Trial of Hematide(TM) in Anemic Cancer Patients Receiving Chemotherapy
- Ecopia to Include Pancreatic Cancer Patients in Its Ongoing Phase I Clinical Trial
- Biomira's Stimuvax Could Benefit Prostate Cancer Patients
- IDM Closes Enrollment to Its EP-2101 Therapeutic Vaccine Trial in Patients With Non-Small Cell Lung Cancer
- Cell Genesys Initiates Second Phase 3 Clinical Trial of GVAX(R) Vaccine for Prostate Cancer
- Cell Genesys Receives Special Protocol Assessment From FDA for Second Phase 3 Trial of GVAX(R) Vaccine for Prostate Cancer
- A.P. Pharma Initiates APF530 Phase 2 Clinical Trial Program in Cancer Patients
 |
 |
User Comments (0)
RSS Feeds